Dupilumab for bullous pemphigoid: Umbrella review of systematic reviews and meta-analyses

By afschroeder • December 16, 2025

Thapa M, Green B, Kasperkiewicz M. Dupilumab for bullous pemphigoid: Umbrella review of systematic reviews and meta-analyses. JAAD Int. 2025 Oct 18;24:172-176. doi: 10.1016/j.jdin.2025.10.004. PMID: 41393351; PMCID: PMC12701699.

Tags: autoantibody, autoimmune blistering disease, bullous pemphigoid, Dermatology, DGSOM Student, Dupilumab, immunobullous disease, Publications, umbrella review

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial

Mease PJ, Chandran V, Armstrong AW, Blanco R, Ogdie A, Siegel EL, Gottlieb AB, Zeng X, Thaçi D, Kishimoto M, Schulze-Koops H, Kivitz A, Dokoupilová[...]

ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype

Assan F, Tragin M, Marella S, Lipecka J, Roger K, Zarhrate M, Bondet V, Nguyen V, Akroun F, Nitschké P, Guerrera IC, Bole C, Izmiryan[...]

A practical inflammatory blood-cell marker for cardiovascular risk stratification in psoriasis: Development of the Platelet-Leukocyte Adjusted Cardiovascular (PLAC) score

Cortes JA, Aflatooni S, Ure A, Palma G, Johnsen N, Smart K, Nong Y, Armstrong AW. A practical inflammatory blood-cell marker for cardiovascular risk stratification[...]